NCCN: Linee-guida MBC Trastuzumab Exposed Anthracyclines Doxorubicin Pegylated Liposomal Doxorubicin Epirubicin Taxanes Paclitaxel Albumin-bound Pacli
{"Image DocumentName": "NCCN: Linee-guida MBC HER2 - HER2 +", "Image ImageDescription": "No compelling evidence that combination regimens are superior to sequential agents. HER2 - HER preferred single agents/combinations listed with no sequencing guidance. Relatively clearer guidance for HER2+ patients. Anthracyclines. Taxanes. Anti-metabolites. First Line (Trastuzumab Na\u00efve) Trastuzumab Exposed. Doxorubicin. Paclitaxel. Albumin-bound Paclitaxel. Capecitabine. Capecitabine + lapatinib. Pegylated Liposomal Doxorubicin. Trastuzumab + Paclitaxel +/- Carboplatin. Gemcitabine. Trastuzumab + Capecitabine. Epirubicin. Docetaxel. Trastuzumab + Docetaxel. Combo/Other. Trastuzumab + lapatinib. Vinorelbine. AC. DC. Trastuzumab + Vinorelbine. FAC/CAF. AT. GP. Trastuzumab + HER2- recommended therapy. FEC. CMF. Other. Trastuzumab + Capecitabine. Bevacizumab.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}